dan 2163 has been researched along with Basal Ganglia Diseases in 17 studies
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " They underwent a series of psychomotor and cognitive tests 1 hour before and 3 and 6 hours after dosing on days 1 and 5." | 2.69 | Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. ( de Bie, A; Louwerens, JW; Milius, H; Muntjewerff, ND; O'Hanlon, JF; Patat, A; Ramaekers, JG; Rosenzweig, P, 1999) |
| " Safety data collection was performed using open reporting, UKU scales or specific extrapyramidal side-effect scales; electrocardiogram recording and vital signs examination; laboratory data collection." | 2.40 | Safety of amisulpride (Solian): a review of 11 clinical studies. ( Coulouvrat, C; Dondey-Nouvel, L, 1999) |
| " Model predictions were used to simulate dose-response and dose-EPS." | 1.46 | A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease. ( Bertrand, J; Brownings, S; D'Antonio, F; Dunn, JT; Greaves, S; Howard, R; Kessler, R; Marsden, P; McLachlan, E; Nair, A; Reeves, S; Smith, A; Taylor, D; Uchida, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Reeves, S | 1 |
| Bertrand, J | 1 |
| McLachlan, E | 1 |
| D'Antonio, F | 1 |
| Brownings, S | 1 |
| Nair, A | 1 |
| Greaves, S | 1 |
| Smith, A | 1 |
| Dunn, JT | 1 |
| Marsden, P | 1 |
| Kessler, R | 1 |
| Uchida, H | 1 |
| Taylor, D | 2 |
| Howard, R | 1 |
| Sparshatt, A | 1 |
| Patel, MX | 1 |
| Kapur, S | 1 |
| Rizos, E | 1 |
| Douzenis, A | 1 |
| Gournellis, R | 1 |
| Christodoulou, C | 1 |
| Lykouras, LP | 1 |
| Molina, JD | 1 |
| Toledo-Romero, F | 1 |
| López-Rodríguez, E | 1 |
| Amorin-Díaz, M | 1 |
| Lerma-Carrillo, I | 1 |
| López-Muñoz, F | 1 |
| Pani, L | 1 |
| Lecrubier, Y | 3 |
| Lambert, TJ | 1 |
| Castle, DJ | 1 |
| Jagadheesan, K | 1 |
| Muirhead, D | 1 |
| Quintin, P | 1 |
| Bouhassira, M | 1 |
| Perrin, E | 1 |
| Lancrenon, S | 1 |
| Limosin, F | 1 |
| Mann, K | 1 |
| Bartels, M | 1 |
| Bauer, H | 1 |
| Gaertner, HJ | 2 |
| Ramaekers, JG | 1 |
| Louwerens, JW | 1 |
| Muntjewerff, ND | 1 |
| Milius, H | 1 |
| de Bie, A | 1 |
| Rosenzweig, P | 1 |
| Patat, A | 1 |
| O'Hanlon, JF | 1 |
| Coulouvrat, C | 1 |
| Dondey-Nouvel, L | 1 |
| Möller, HJ | 1 |
| Delcker, A | 1 |
| Schoon, ML | 1 |
| Oczkowski, B | 1 |
6 reviews available for dan 2163 and Basal Ganglia Diseases
| Article | Year |
|---|---|
Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Monitoring | 2009 |
Clinical implications of dopamine research in schizophrenia.
Topics: Amisulpride; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Receptors, Dopamine; Res | 2002 |
Amisulpride: progress and outcomes.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Quality of Life; Receptors, Dopam | 2002 |
Pharmacological approaches to the management of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiaze | 2003 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
Safety of amisulpride (Solian): a review of 11 clinical studies.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Blood Cell Count | 1999 |
5 trials available for dan 2163 and Basal Ganglia Diseases
| Article | Year |
|---|---|
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Topics: Adult; Affect; Amisulpride; Antipsychotic Agents; Attention; Basal Ganglia Diseases; Benzodiazepines | 2006 |
Amisulpride--an open clinical study of a new benzamide in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Electroe | 1984 |
Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.
Topics: Adult; Affective Disorders, Psychotic; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Co | 1999 |
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; | 2001 |
Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Halop | 1990 |
6 other studies available for dan 2163 and Basal Ganglia Diseases
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Basal Ganglia Diseases; Brain; Delusions; D | 2017 |
Tardive dyskinesia in a patient treated with quetiapine.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dibenzothiazepines; Dyskine | 2009 |
Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagn | 2011 |
Improvement of amisulpride-induced extrapyramidal symptoms with quetiapine.
Topics: Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Humans; Male; M | 2004 |
Is amisulpride an 'atypical' atypical antipsychotic agent?
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Limbic System; Receptors, Dopamin | 2000 |